RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Daqing Wu to Drug Discovery

Back to Details
This is a "connection" page, showing publications Daqing Wu has written about Drug Discovery.
Daqing Wu
Connection Strength
0.725
Drug Discovery
  1. Li X, Gera L, Zhang S, Chen Y, Lou L, Wilson LM, Xie ZR, Sautto G, Liu D, Danaher A, Mamouni K, Yang Y, Du Y, Fu H, Kucuk O, Osunkoya AO, Zhou J, Wu D. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Theranostics. 2021; 11(14):6873-6890.
    View in: PubMed
    Score: 0.725
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support